XML 31 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Background, Basis of Presentation, Economic Dependency and Significant Accounting Policies: - Basis of Presentation thru Fair Value of Financial Instruments (Details)
12 Months Ended
Feb. 28, 2018
USD ($)
item
shares
Feb. 28, 2017
USD ($)
shares
Percentage of outstanding stock owned by the President and Chairman of the Board 81.00%  
Number of antineoplaston drugs that have received FDA approval | item 0  
Economic Dependency    
Significant external revenue $ 0 $ 0
Working capital deficit 107,700  
Accumulated deficit 120,385,630 118,773,529
Losses incurred 1,612,101 1,504,717
Income Taxes    
Uncertain tax positions $ 0 $ 0
Loss Per Common Share    
Warrants and stock options excluded from calculation of diluted loss per share (in shares) | shares 1,600,000 1,600,000
Fair Value of Financial Instruments    
Number of financial instruments held for trading purposes | item 0  
Minimum    
Economic Dependency    
Estimated useful lives 5 years  
Maximum    
Economic Dependency    
Estimated useful lives 10 years